Get access
Clinical & Experimental Allergy

The inhibitory effect of azelastine hydrochloride on histamine- and allergen-induced bronchoconstriction in atopic asthma

Authors

  • P. RAFFERTY,

    1. Immunopharmacology Group, Medicine 1, Level D, Centre Block, Southampton General Hospital, Southampton, U.K.
    Search for more papers by this author
  • S. T. HOLGATE

    Corresponding author
    1. Immunopharmacology Group, Medicine 1, Level D, Centre Block, Southampton General Hospital, Southampton, U.K.
      Prof. S. T. Holgate, Immunopharmacology Group, Medicine 1, Level D, Centre Block, Southampton General Hospital, Tremona Road, Southampton SO9 4XY, U.K.
    Search for more papers by this author

Prof. S. T. Holgate, Immunopharmacology Group, Medicine 1, Level D, Centre Block, Southampton General Hospital, Tremona Road, Southampton SO9 4XY, U.K.

Summary

We have examined the effect of azelastine, a new H1 histamine receptor antagonist, against bronchoconstriction induced by histamine and allergen. Twelve mild, atopic asthmatics each underwent two histamine and two allergen concentration-response inhalation challenges 4 hr after treatment with either 8.8 mg of azelastine or a matched placebo. Following azelastine the dose of histamine required to provoke a 20% fall in FEV1 (PD20 histamine) rose, from a geometric mean of 0.31 mg/ml to < 13.2 mg/ml. Azelastine also significantly inhibited allergen-induced bronchoconstriction, the PD20 allergen rising from 9.3 cumulative breath units (c.b.u.) to < 47.9 c.b.u., a greater than 5-fold increase. We conclude that azelastine effectively inhibits both histamine and allergen-induced bronchoconstriction, with considerably greater potency against histamine.

Get access to the full text of this article

Ancillary